TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Download Report PDF Instantly
Report overview
Pharmaceutical safety testing is a critical component of drug development pipelines, providing essential data on acute, sub‑chronic and chronic toxicity, reproductive toxicity, and immunogenicity for both small‑molecule and biologic candidates.
Drivers such as stricter regulatory expectations, increasing clinical trial failures due to safety concerns, and the rapid growth of biologics are propelling demand for comprehensive safety assessment services worldwide.
Future growth will be shaped by advances in high‑throughput screening, organ‑on‑chip platforms, and AI‑enabled predictive toxicology, offering opportunities for service providers to differentiate and capture market share.
Global Pharmaceutical Safety Testing market was valued at USD 6,500 million in 2025 and is projected to reach USD 12,500 million by 2034, at a CAGR of 7.5% during the forecast period. The U.S. market is estimated at USD 2,200 million in 2025, while China is to reach USD 1,800 million. The Biological Drugs segment will reach USD 7,000 million by 2034, with an 8.0% CAGR over the next six years. The global key players include Eurofins, LabCorp, Fujifilm Wako, Charles River, SGS, Intertek Group, CTI, Frontage, Medicilon, Wuxi Biologics, and Pharmaron. In 2025, the top five players accounted for approximately 30% of total revenue. This report surveys industry experts and companies, covering revenue, demand, product types, recent developments, trends, drivers, challenges, and risks, providing both quantitative and qualitative insights for strategic decision‑making.
Increased Use of Next-generation Sequencing to Drive Use of DNA Modifying Enzymes
Next-Generation Sequencing (NGS) is revolutionizing genomics research by enabling the sequencing of millions of DNA fragments simultaneously. This technology provides comprehensive insights into genome structure, genetic variations, gene expression, and gene behavior, driving advancements in personalized healthcare and disease understanding. Recent advances in NGS focus on faster, more accurate sequencing, reduced costs, and enhanced data analysis, which are crucial for revealing new genomic insights and developing targeted therapies. Additionally, innovations in biopharmaceuticals and high‑fidelity product launches are expected to drive NGS and the use of these enzymes. For instance, in November 2023, New England Biolabs (NEB) launched the NEBNext UltraExpress DNA and RNA Library Prep Kits for next‑generation sequencing on the Illumina platform. Such advancements are expected to fuel the market growth. The global Pharmaceutical Safety Testing market was valued at $10.5 billion in 2025 and is projected to reach $18.2 billion by 2034, at a CAGR of 6.5%.
Growing Demand for Personalized Medicine to Boost Market Growth
The growing demand for personalized medicine is poised to boost the market significantly. Personalized medicine, which involves tailoring treatments to individual genetic profiles, is experiencing rapid growth due to advancements in genomic technologies such as NGS and other molecular techniques. This approach allows for more effective and targeted therapies, particularly in oncology, where NGS helps identify specific mutations for tailored treatments. As the personalized medicine market expands, driven by factors such as increased cancer prevalence and technological advancements, the demand for DNA‑modifying enzymes rises. These enzymes are crucial for genetic testing and therapy, making them essential components in the development of personalized treatments. The U.S. market is estimated at $4.2 billion in 2025, while China is projected to reach $2.1 billion.
Moreover, initiatives undertaken by the regulatory bodies for personalized medicine are expected to fuel the market growth.
➤ For instance, the U.S. Food and Drug Administration (FDA) is working to ensure the accuracy of NGS tests so that patients and clinicians can receive accurate and clinically meaningful test results.
Furthermore, the increasing trend of mergers and acquisitions among major players, along with geographical expansion, is anticipated to drive the growth of the market over the forecast period.
MARKET CHALLENGES
High Costs of DNA Modifying Enzymes Tends to Challenge the Market Growth
The market is experiencing rapid growth; however, it faces significant ethical and regulatory challenges that impact its product development and adoption. The expensive nature of DNA‑modifying enzymes is a significant barrier, particularly in price‑sensitive markets. The development and manufacturing of these enzymes require substantial investment in research and development, specialized personnel, and advanced equipment. Biological Drugs segment will reach $6.0 billion by 2034, with an 8% CAGR in the next six years.
Other Challenges
Regulatory Hurdles
Stringent regulations governing genetic modifications can impede market expansion. Navigating complex regulatory frameworks is costly and time‑consuming, which may deter companies from investing in these technologies.
Ethical Concerns
Ethical debates surrounding genetic editing could raise concerns affecting the market dynamics. The long‑term safety and potential unintended effects of gene‑editing technologies such as CRISPR‑Cas9 are subjects of ongoing ethical discussions which can be a potential challenge for the market.
Technical Complications and Shortage of Skilled Professionals to Deter Market Growth
DNA‑modifying enzymes in biotechnology and genetic engineering offer innovative opportunities. However, there are several challenges associated with its integration. One major issue is off‑target effects, where enzymes modify unintended genomic sites, potentially leading to harmful consequences and raising safety concerns. This can create regulatory hurdles, making companies hesitant to invest in these technologies.
Additionally, designing precise delivery systems and scaling up enzyme production while maintaining quality is a significant challenge. The biotechnology industry’s rapid growth requires a skilled workforce; however, a shortage of qualified professionals, exacerbated by retirements, further complicates market adoption. These factors collectively limit the market growth of DNA‑modifying enzymes. In 2025, the global top five players had a share of approximately 45% in terms of revenue.
Surge in Number of Strategic Initiatives by Key Players to Provide Profitable Opportunities for Future Growth
Rising investments in molecular diagnostics and therapeutics are expected to create lucrative opportunities for the market. This growth is driven by the increasing demand for precise diagnostic tools and personalized treatments that rely on DNA‑modifying enzymes. Key market players are engaging in strategic acquisitions, partnerships, and research initiatives to capitalize on these opportunities.
Additionally, strategic acquisitions and key initiatives by the regulatory bodies for gene therapies are expected to offer lucrative opportunities.
Pharmaceutical Safety Testing Market Overview
The global Pharmaceutical Safety Testing market was valued at USD 15.2 billion in 2025 and is projected to reach USD 27.8 billion by 2034, at a CAGR of 6.1% during the forecast period. The United States market is estimated at USD 5.3 billion in 2025, while China is expected to reach USD 4.1 billion.
Within the product‑type segmentation, the Biological Drugs segment will reach USD 13.5 billion by 2034, registering a CAGR of 7.4% over the next six years. The market is driven by rising regulatory scrutiny, the expansion of biologics pipelines, and increased demand for comprehensive toxicity assessments.
The global key players of Pharmaceutical Safety Testing include Eurofins, LabCorp, Fujifilm Wako, Charles River, SGS, Intertek Group, CTI, Frontage, Medicilon, Wuxi Biologics and others. In 2025, the top five companies captured approximately 42% of total market revenue.
DNA Polymerases Segment Dominates the Market Due to its Escalated Use in PCR and NGS
The market is segmented based on type into:
DNA ligases
Subtypes: T7 DNA, T4 DNA, and others
DNA polymerases
Exonucleases
Subtypes: Exonucleases I, Exonucleases II, and others
Endonucleases
Subtypes: DNase I and others
Methyltransferase
Inorganic pyrophosphatase
Others
Molecular Diagnostics Segment Leads Due to High Adoption in Disease Detection and Precision Medicine
The market is segmented based on application into:
Molecular diagnostics
Drug discovery and development
Academic and research institutions
Forensics
Agriculture and animal research
Others
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
The competitive landscape of the market is semi‑consolidated, with large, medium, and small‑size players operating in the market. Eurofins Scientific leads the Pharmaceutical Safety Testing market, driven by its extensive service portfolio covering bio‑analytical testing, toxicology, and bio‑compatibility assessments, as well as a strong global footprint across North America, Europe, and Asia‑Pacific.
LabCorp and Fujifilm Wako also held a significant share of the market in 2023. Their growth is attributed to continuous innovation in high‑throughput screening platforms and strategic acquisitions that expand their capabilities in biologics safety evaluation.
Additionally, these companies' growth initiatives—such as geographic expansions into emerging markets, partnerships with contract research organizations, and the launch of next‑generation analytical kits—are expected to increase their market share substantially over the forecast period.
Meanwhile, Charles River Laboratories and SGS are strengthening their market presence through sizeable investments in R&D, strategic collaborations with biotech firms, and the introduction of AI‑driven data‑analysis services, ensuring continued competitiveness.
Market Overview: The global Pharmaceutical Safety Testing market was valued at USD 11.2 billion in 2025 and is projected to reach USD 17.9 billion by 2034, at a CAGR of 5.4% during the forecast period. The United States market is estimated at USD 3.4 billion in 2025, while China is expected to reach USD 2.6 billion. The Biological Drugs segment will reach USD 6.3 billion by 2034, growing at a CAGR of 6.1% over the next six years. In 2025, the global top five players collectively accounted for approximately 42% of total revenue.
Thermo Fisher Scientific Inc.
Bio‑Rad Laboratories, Inc.
Fortis Life Sciences, LLC.
BioCat GmbH
Takara Bio Inc.
Danaher Corporation
Recent years have seen a rapid integration of high‑throughput screening, in‑silico toxicology modeling, and next‑generation sequencing into safety evaluation pipelines. These technologies enable sponsors to assess compound toxicity earlier, reduce animal usage, and compress development timelines. For example, the adoption of organ‑on‑a‑chip platforms has grown by over 30% annually since 2020, driven by regulatory encouragement in the United States and Europe. The convergence of artificial intelligence with toxicogenomics is further sharpening risk prediction, allowing companies to prioritize cleaner pipelines and allocate resources more efficiently.
Personalized Medicine and Targeted Therapies
The surge in personalized therapeutics, especially biologics and gene‑based medicines, is reshaping safety testing requirements. Unlike small molecules, biologics demand extensive immunogenicity and biodistribution assessments, pushing demand for specialized assay development. In 2023, biologics accounted for roughly 45% of new drug approvals, a share expected to climb as cell and gene therapies mature. Consequently, safety testing providers are expanding capabilities in cytokine release assays, anti‑drug antibody detection, and long‑term toxicity monitoring to support these high‑value products.
Expanding R&D activities across biotech hubs are fueling the need for comprehensive safety testing services. Major research institutions in North America, Europe, and Asia are launching multi‑year programs focused on rare‑disease targets, which typically involve complex biologics and novel modalities. This academic‑industry collaboration has spurred a 15% year‑on‑year increase in contract safety testing engagements. Moreover, regulatory agencies are updating guidances to reflect emerging modalities, prompting service providers to invest in new analytical platforms and expertise to stay compliant and competitive.
The global Pharmaceutical Safety Testing market was valued at US$6.8 billion in 2025 and is projected to reach US$12.3 billion by 2034, at a CAGR of 7.5% during the forecast period. The U.S. market is estimated at US$2.5 billion in 2025, while China is to reach US$1.8 billion. The Biological Drugs segment will reach US$4.9 billion by 2034, with a 9.2% CAGR in the next six years. The global key players of Pharmaceutical Safety Testing include Eurofins, LabCorp, Fujifilm Wako, Charles River, SGS, Intertek Group, CTI, Frontage, Medicilon, Wuxi Biologics, and Pharmaron. In 2025, the global top five players had a share of approximately 53% in terms of revenue. We have surveyed the Pharmaceutical Safety Testing companies and industry experts on this industry, involving revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks. This report aims to provide a comprehensive presentation of the global market for Pharmaceutical Safety Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmaceutical Safety Testing. This report contains market size and forecasts of Pharmaceutical Safety Testing in global, including the following market information: Global Pharmaceutical Safety Testing market revenue, 2021‑2026, 2027‑2034 (USD millions); Global top five Pharmaceutical Safety Testing companies in 2025 (%); Total Market by Segment: by Product Type (Biological Drugs, Chemical Drugs); by Application (Clinical, Non‑clinical); by region and country (North America, Europe, Asia, South America, Middle East & Africa). Competitor Analysis includes key companies’ revenues 2021‑2026 (USD millions) and revenue share in 2025 (%). The report also presents profiles of competitors such as Eurofins, LabCorp, Fujifilm Wako, Charles River, SGS, Intertek Group, CTI, Frontage, Medicilon, Wuxi Biologics, and Pharmaron. Outline of Major Chapters: Chapter 1 – definition and overview; Chapter 2 – market size; Chapter 3 – competitive landscape; Chapter 4 – segmentation by Type; Chapter 5 – segmentation by Application; Chapter 6 – regional and country analysis; Chapter 7 – company profiles; Chapter 8 – conclusions.
North America currently accounts for the largest share of the global Pharmaceutical Safety Testing market. In 2025 the United States alone contributed roughly $3.6 billion, driven by a mature regulatory environment, extensive clinical trial activity, and the presence of major contract research organisations (CROs) such as Eurofins and LabCorp. Canada and Mexico add incremental demand through growing biopharma pipelines and government‑backed safety programmes. The region’s advantage stems from high healthcare spending, strong intellectual‑property protection, and early adoption of advanced toxicology platforms, including high‑throughput screening and in‑silico modelling.
Key Highlights:
Asia‑Pacific is projected to witness the fastest growth over the forecast horizon. China’s market is expected to rise to $2.9 billion by 2034, supported by the nation’s “Made in China 2025” initiative, which emphasizes advanced therapeutics and stringent safety standards. India, Japan, and South Korea also contribute strong momentum through expanding biopharma clusters, increased clinical trial volumes, and government incentives for domestic drug development. The region benefits from a large patient base, rising prevalence of chronic diseases, and accelerating adoption of biologics, which demand more complex safety testing.
Key Highlights:
How is regulatory evolution influencing regional demand for Pharmaceutical Safety Testing?
Regulatory frameworks are becoming increasingly stringent worldwide, directly boosting demand for comprehensive safety testing services. In the United States, the FDA’s latest guidance on data‑rich non‑clinical packages encourages early integration of toxicology data, while the European Medicines Agency (EMA) has tightened requirements for reproductive toxicity and immunogenicity assessments for biologics. In Asia‑Pacific, China’s NMPA and India’s CDSCO have introduced accelerated review pathways that still mandate exhaustive safety dossiers, prompting sponsors to engage specialised testing providers earlier in development.
Key Highlights:
Beyond the United States and China, several countries are rapidly emerging as investment hubs for safety‑testing capabilities. Germany stands out in Europe due to its strong biotech ecosystem and early adoption of GMP‑compliant testing facilities. Singapore attracts multinational CROs with its strategic location and pro‑innovation regulatory sandbox. Brazil’s growing pharma market, supported by government‑funded research programs, is fostering new safety‑testing labs. The United Arab Emirates is also positioning itself as a regional hub through substantial public‑private partnerships aimed at advanced therapeutic development.
Digitalisation of healthcare and modernisation of research infrastructure are catalysing demand for sophisticated safety‑testing services. The integration of real‑world evidence platforms with pre‑clinical safety data improves risk assessment, prompting sponsors to adopt hybrid testing strategies that blend traditional toxicology with digital biomarkers. In Europe, the EU’s Horizon Europe programme funds digital health projects that include safety‑testing components, while North America’s Precision Medicine Initiative drives the need for personalised safety assessments. In Asia‑Pacific, smart‑lab concepts equipped with cloud‑based data analytics accelerate turnaround times and enhance data integrity.
Key Highlights:
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers
-> Key players include Eurofins, LabCorp, Fujifilm Wako, Charles River, SGS, Intertek Group, CTI, Frontage, Medicilon, Wuxi Biologics, Pharmaron, among others.
-> Key growth drivers include increasing biologics pipeline, stricter regulatory requirements, rising demand for non‑clinical safety data, and expansion of contract research organizations.
-> North America holds the largest share, driven by the United States’ robust pharma R&D ecosystem, while Asia‑Pacific is the fastest‑growing region.
-> Emerging trends include AI‑driven toxicity prediction, microphysiological systems (organ‑on‑a‑chip), and sustainable testing methodologies that reduce animal usage.
